Back to UBS Group AG UBS Group AG

HALOHALO
Showing 8 of 30 quarters

Position history for UBS Group AGUBS Group AG's holdings in HALOZYME THERAPEUTICS INC

UBS Group AG holds 1.5M shares of HALO (HALOZYME THERAPEUTICS INC), worth $116.8M as of 2026-Q2. The position was increased (+63.3% shares). HALO represents 0.0% of UBS Group AG's portfolio.

Current Value

$116.8M

Current Shares

1.5M

Total Value Change

+$96.4M

Total Shares Change

+1.1M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1.5M
+63.3%
$116.8M0.0%$78.27
44
2026-Q1
Decreased
914,003
-33.1%
$59.1M0.0%$69.40
0
2025-Q4
Decreased
1.4M
-53.6%
$91.9M0.0%$67.70
0
2025-Q3
Increased
2.9M
+93.2%
$216M0.0%$73.29
49
2025-Q2
Increased
1.5M
+334.0%
$79.3M0.0%$52.21
48
2025-Q1
Decreased
351,231
-43.2%
$22.4M0.0%$63.84
0
2024-Q4
Increased
618,774
+74.0%
$29.6M0.0%$47.99
43
2024-Q3
Decreased
355,526
-0.1%
$20.4M0.0%$56.97
0

Other major holders of HALO: BNP PARIBAS FINANCIAL MARKETS, BlackRock, Inc., BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used